University of California, San Francisco, Psoriasis and Skin Treatment Center, San Francisco, California 94118, USA.
J Dermatolog Treat. 2011 Apr;22(2):75-8. doi: 10.3109/09546630903559814. Epub 2010 Jun 5.
Etanercept and adalimumab are the most widely used biologic agents for psoriasis today. Large phase III trials have elucidated the much higher efficacy of adalimumab over etanercept; however, no head-to-head comparison data exist for these two medications.
We report four cases of patients well controlled with Enbrel who flared when switched to adalimumab. In all four cases, the patient's psoriasis improved when switched back to etanercept.
This brief report is intended to alert clinicians of the possibility that, despite the well-known average efficacy advantage of adalimumab over etanercept, some psoriasis patients experience better clinical outcome with etanercept than adalimumab. Therefore, despite the general efficacy difference between these two TNF inhibitors, it may be worth keeping in mind etanercept as an option in patients who have failed with adalimumab.
依那西普和阿达木单抗是目前最广泛应用于银屑病的生物制剂。大型 III 期临床试验阐明了阿达木单抗相对于依那西普的更高疗效；然而，这两种药物之间没有头对头的比较数据。
我们报告了 4 例恩利治疗有效的患者在换用阿达木单抗后出现病情加重。在所有 4 例患者中，当换回依那西普时，患者的银屑病得到改善。
本简要报告旨在提醒临床医生注意到，尽管阿达木单抗的平均疗效优于依那西普，但一些银屑病患者使用依那西普的临床效果优于阿达木单抗。因此，尽管这两种 TNF 抑制剂之间存在一般的疗效差异，但对于那些对阿达木单抗治疗失败的患者，依那西普可能是一个值得考虑的选择。
